7623-03-2

Upstream product

• 20849-78-9 p-(beta-chloroethyl)benzoic acid 

Downstream Products

• 1622204-10-7 5-((2-(4-(2-(4-ethylpiperazin-1-yl)ethyl)benzamide)pyridin-4-yl)oxy)-6-methoxy-N-methyl-1H-indole-1-carboxamide 

Relevant academic research and scientific papers

Pairwise Proximity-Differentiated Visualization of Single-Cell DNA Epigenetic Marks

Spatial positioning and proximity of relevant biomolecules such as DNA epigenetic marks are fundamental to a deeper understanding of life. However, it remains poorly explored and technically challenging. Here we report the pairwise proximity-differentiate

5-FORMYLCYTOSINE SPECIFIC CHEMICAL LABELING METHOD AND RELATED APPLICATIONS

The present invention relates to a 5-formylcytosine specific chemical labeling method and related applications in aspects such as sequencing, detection, imaging, and diagnosis. In the method, a condensation reaction occurs between an active methylene grou

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

5-SUBSTITUTED-1, 4-BENZ0DIAZEPINES AS PHOSPHODIESTERASE INHIBITORS

Novel 7, 8 dialkoxy-5 - (amino alkyl phenyl) - 1, 4 -benzodiazepines of formula I with said amino being substituted or forming a nitrogen containing heterocyclic alkyl ring, which 1, 4- benzodiazepines are inhibitors of phosphordiesteraste type IV (PDE-4)

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the

CYCLIC TERTIARY AMINE COMPOUND

The present invention provides a cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytokines. It is either a compound having a structure represented by the following general formula (I): (wherein A represents an optionally substituted trivalent group derived from pyrimidine, pyrrole, or the like; R1 represents an aryl or a heteroaryl group which may optionally be substituted; R2 represents a heteroaryl group which may optionally be substituted; and R3 represents a cyclic tertiary amino group) or a pharmacologically acceptable salt of the compound.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In anot